MEDICATION AGAINST ESTROGEN-RECEPTOR b (ER.beta) POSITIVE BREAST TUMOR

A method for treatment of a patient suffering from estrogen-receptor β (ERβ) positive breast tumor, comprising administering to a patient in need of the treatment a steroid compound 4-hydroxyandrost-4-ene-3,17-dione (4-OHA) of formula I

• Formula I, or ester thereof, as a prodrug, wherein said prodrug is applied topically to the patient.

A method for treatment of a patient suffering from estrogen-receptor β (ERβ) positive breast tumor, comprising administering to a patient in need of the treatment 4-Hydroxytestosterone (4-OHT) or 4-Hydroxy-5-alpha-androstane-3-beta,17beta-diol (4-OHBA) or the respective hydroxy-esters of 4-OHT or 4-OHBA, wherein 4-OHT or 4-OHBA or the respective hydroxy-esters of 4-OHT or 4-OHBA is applied topically to the patient.

The method according to claim 6, wherein the patient suffers from triple negative breast cancer in terms of estrogen-receptor α (ERα) negative, progesterone-receptor (PR) negative and HER2-receptor negative, comprising administering 4-OHT.

A method for treatment of a patient suffering from estrogen-receptor β (ERβ) positive breast tumor, comprising administering to a patient in need of the treatment a pharmaceutical composition suitable for topical application comprising the steroid compound 4-hydroxyandrost-4-ene-3,17-dione (4-OHA) of formula I

• Formula I, or ester thereof,
• as a prodrug and pharmaceutically acceptable carrier(s) and/or excipient(s).

A method for treatment of ERβ-positive breast cancer tissue, comprising a pre-surgical topical administration of 4-OHA or ester thereof as a prodrug.